Macro Research

Is this EM powerhouse cheap to enter after the recent rout?

Indian equities have largely declined since early December. The Adani controversy has also added fuel to the fire, causing the market to slide further. Are valuations giving the green light now?

  • |
  • Published on 17 Feb 2023

Is this EM powerhouse cheap to enter after the recent rout? | Open a FREE FSM account and manage all your investments conveniently in ONE place

  • We turned negative on Indian equities and downgraded its Star Rating back in October 2022. One of the key reasons anchoring this downgrade was the region’s lofty valuations which reduced the upside potential and raised the risk of de-rating.

  • Since our update, valuations have declined slightly but the Sensex Index is still trading at a 20% premium to the long-term average. Indian equities also remain pricey relative to Asian equities, despite the recent rally in north Asian and ASEAN equities.

  • If a global recession were to materialise this year (our base case), Indian equities will be entering it with historically high valuations, akin to levels seen during the global financial crisis and the pandemic. We see a high risk of a significant valuation compression in a recession.

  • While near-term risks are present, India’s growth potential remains firmly intact and is one key reason why we are keeping Indian equities on our radar. Powerful and synergistic domestic tailwinds, as well as positive reforms, buttress India’s long-term growth potential.

  • We maintain our cautious view as upside potential remains muted due to steep valuations. While we acknowledge India’s growth potential, we are hesitant to pay an extended premium at this point. That said, we are keeping Indian equities on our watch list and await a better point of entry.

Lofty valuations were one of the key reasons we turned negative on Indian equities


In October 2022, we turned negative on Indian equities and downgraded its Star Rating from 2.5 Stars “Neutral” to 2.0 Stars “Not Attractive”. One of the key reasons anchoring this downgrade was valuations, which were not only inflated on a historical basis but also much steeper relative to regional equities.  Other concerning factors were the risk of earnings downgrade and an unsustainable recovery.

In 3Q 2022, valuations were driven higher after the rally in early October, pushing the forward PE close to 23X, which was a 21% premium relative to the long-term average. This also made Indian equities much pricier in comparison to the larger basket of Asian stocks (gauged by the MSCI Asia ex-Japan Index). While Indian equities tend to trade at a higher forward PE ratio than Asian equities, this premium widened further in 3Q 2022 as valuations for the former rose while that of the latter fell. 

The elevated valuations also meant that the longer-term upside potential for Indian equities has fallen and is less attractive. We forecasted a 10% upside by FY2025 (end-March 2025) back in October. Besides the unappealing upside potential, lofty valuations also raise the risk of a de-rating as multiples come under greater pressure, especially with heightened macro headwinds. 

Related article:

Have valuations come down after the recent market rout?


Indian equities have largely been on a decline since early December. More recently, the Adani controversy has also caused equities to slide further as markets remain jittery after the news was brought to light. However, valuations (in terms of forward PE) have only declined marginally despite the market rout as earnings estimates were revised downwards in the same period. With the Sensex Index currently trading at a forward PE of 22.8X, this leaves valuation elevated compared to history – almost 20% premium to the long-term average.

Related article:

On a slightly positive note, Indian equities are now less pricey relative to Asian equities. The recent flurry of positive news from China has not only uplifted Chinese equities but also supported the broader Asian equity markets, driving PE multiples higher. Valuations for Indian equities did not follow and instead declined marginally for the reasons highlighted above. 

However, this is not convincing enough for us. Valuations in comparison to regional peers might have declined but Indian equities are by no means cheap. Relative valuations (gauged by the forward PE ratio of India over Asia ex-Japan equities) has declined from a peak premium of 121% (Oct ’22) to 80%, which is still much higher than the historical average premium of 53%. Simply put, Indian equities are almost 1.8X more expensive relative to Asian equities. 

This can also be observed when comparing valuations across Asian equity markets. Within Asia, Indian equities are still expensive as the region not only trades at the highest forward PE ratio amongst its Asian peers, but also a staggering 32% premium over Thailand, which is the next most expensive Asian market after India, with a forward PE ratio of 17.3X. 

Chart 1: Relative valuation has declined – Indian equities have become cheaper relative to Asia ex-Japan equities

 

Chart 2: India is the most expensive equity market in Asia

 

Indian equities might enter recession with historically high valuations. Bad news always follow


If a global recession were to materialise this year (our base case), Indian equities will be entering it with historically high valuations. These are levels similar to the 2008 global financial crisis and the 2020 pandemic, during which valuations contracted significantly shortly after, driven by a plunge in share prices (Chart 3). 

During the global financial crisis, from peak to trough, the forward PE ratio fell from 24X to 12X (Jan ’08 – Jul ’08) before expanding to 15X, helped by the relief rally, and then ultimately falling from 15X to 8X (Aug ’08 – Oct ’08). Similarly, during the pandemic in 2019, the forward PE ratio fell from 24X to 19X. In both scenarios, Indian equities entered the recession with lofty valuations, far above the long-term average.

While there are only two periods of observations due to the availability of data, both bear striking similarities. Additionally, comparable observations can be made across other Indian equity indices, such as the MSCI India Index and the Nifty 50 Index (Chart 4). With strong corroborations by historical data, we believe Indian equities are at risk of a major valuation contraction when a global recession materialises, and this implies further downside ahead. Aside from a recession-triggered valuation de-rating, a deceleration in India’s economic growth or a global risk-off episode are also potential catalysts for a valuation contraction. 

Chart 3: Indian equities will be entering a recession with historically high valuations, akin to levels seen during the GFC and pandemic



Chart 4: Same observation across other major Indian equity indices

 

Expect further earnings downgrades


Earnings estimates for the Sensex Index have seen a -2% downward revision in FY2023. Thus far, the downgrade in earnings estimates has been largely driven by cyclical sectors like energy, materials, and industrials. Reliance Industries, an index heavyweight and one of the constituents of the energy sector, saw steep downgrades over the past quarter. The materials sector has also been hit with broad-based downgrades from Tata Steel, Asian Paints, and Ultratech Cement. Larsen & Toubro, a construction leader and industrial sector constituent, was also hit with major downgrades.

While earnings downgrades are a common occurrence (Chart 5), what we remain concerned about is further cuts moving forward, suggesting a higher risk of equity downside. This is a likely outcome in 2023 as weakening economic growth will further erode corporate profitability, especially for pro-cyclical companies. Thus far, India’s recovery has been driven by a combination of consumption, exports, and investment spending – we think only the latter may sustain this year. 

Domestic consumption has started to moderate as pent-up demand runs its course and high inflation pressures households. While services remain resilient, goods consumption is weakening. Exports growth is likely to decelerate as global demand softens, and this negative outlook has been further supported by deteriorating data from the manufacturing PMI’s new orders sub-component. With global growth decelerating and domestic drivers likely to give way, India’s growth should slow further this year, putting pressure on corporate earnings. We expect earnings downgrades of around -10% in FY24, similar to what we highlighted in our previous update. 

Chart 5: Indian equities tend to experience EPS downgrades across the fiscal year

 

Secular opportunities abound and unhindered

 
While nearer-term risks are present, we are still keeping Indian equities on our radar. A major reason is its secular growth potential, which remains firmly intact, as highlighted in our previous update. On one hand, powerful and synergistic domestic tailwinds, such as demographic dividends, middle-class transformation, and consumption evolution, help drive a positive long-term consumer story. On the other, positive reforms in recent years, such as the production-linked incentive scheme, as well as the continuing reform momentum, have also bolstered the nation’s long-term growth.

We believe one of India’s biggest secular tailwinds will come from its position as a key beneficiary of the ‘China plus one’ strategy, which is an ongoing move by multinational companies to divest and relocate supply chains away from China. With the combination of a young and educated labour force, government incentives, and established infrastructures, India has met the demands that many multinational companies seek. As such, it is a prime destination. The government has made efforts to draw investments away from China to India in recent years and we expect further measures to support companies pursuing a ‘China plus one’ strategy, especially in securing a larger share of the global supply chain.

Waiting for a better entry point


With our designated fair PE of 19.0X and revised EPS projections over the next two years, we project a maximum upside potential of 9% by March 2025 (end-FY2025). The upside potential remains muted due to steep valuations and is less appealing when compared to other Asian equity markets, as many boast much cheaper valuations. Together, the unattractive upside potential and the risk of a de-rating continue to be key reasons why we remain negative on Indian equities. 

While we acknowledge the strong secular growth opportunities in India, which is an attractive trait amongst emerging markets, we are hesitant to pay a big premium for it – at least not when many Asian and emerging market peers are trading cheaply. As such, we are keeping Indian equities on our watch list and waiting for re-entry once valuations become more palatable and risk subsides. 

Our recommended fund is the UTI India Dynamic Equity USD. For investors who are concerned about the Adani controversy, it is worth noting that the fund does not have any exposure to Adani stocks. Most of the Adani Group companies belong to the commodities, energy, utilities, and infrastructure sectors. The fund has stayed away from these areas as the portfolio managers lacked conviction about the ability of these businesses to maintain healthy balance sheets and generate a high return on capital across cycles. The fund remains our pick to tap on India’s growth story due to its strong track record, backed by its ability to select high-quality and high-growth companies. 


Chart 6: Earnings forecast and price performance of the Sensex Index


Table 1: Projected upside for Indian equities 

India (Sensex Index)

FY2022

FY2023

FY2024

FY2025

   PE ratio (X)

22.0

22.8

21.1

17.8

   Projected earnings growth (YoY %)

29.3%

20.1%

7.8%

18.5%

   Projected Earnings Per Share (EPS)

2,250

2,703

2,914

3,452

   Target price (Based on 19.0X Fair PE ratio)

-

-

-

67,000

   Potential upside (%)

-

-

-

8.9%

Source: Bloomberg Finance L.P., iFAST estimates.

Data as of 16 Feb 2023. *Fiscal year 1st April to 31st March.


Table 2: Recommended Products


Declaration:
For specific disclosure, at the time of publication of this report, IFPL (via its connected and associated entities) and the analyst who produced this report hold a NIL position in the abovementioned securities.

The Research Team is part of iFAST Financial Pte Ltd.    

All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.

Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).

iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.

Ways to Invest with FSM Global
Why FSM Global
Don't have an account with us?
Open an account here
Need Financial Advice?
Make an appointment

We use cookies If you close this message or continue to use this site, you will consent to the use of Cookies, unless you choose to disable them. Click on our Privacy Policy to understand more.